Pharmacogenetic analysis of GLCCI1 in three north European pediatric asthma populations with a reported use of inhaled corticosteroids

Susanne J H Vijverberg; Roger Tavendale; Maarten Leusink; Leo Koenderman; Jan A M Raaijmakers; Dirkje S Postma; Gerard H Koppelman; Steve W Turner; Somnath Mukhopadhyay; Colin N A Palmer; Anke Hilse Maitland-van der Zee; Stephen William Turner

doi:10.2217/pgs.14.37

Pharmacogenetic analysis of GLCCI1 in three north European pediatric asthma populations with a reported use of inhaled corticosteroids

Susanne J H Vijverberg, Roger Tavendale, Maarten Leusink, Leo Koenderman, Jan A M Raaijmakers, Dirkje S Postma, Gerard H Koppelman, Steve W Turner, Somnath Mukhopadhyay, Colin N A Palmer, Anke Hilse Maitland-van der Zee, Stephen William Turner

Research output: Contribution to journal › Article › peer-review

21 Citations (Scopus)

Abstract

BACKGROUND: GLCCI1 rs37972 has previously been associated with decreased lung function improvement upon treatment with inhaled corticosteroids (ICS) in asthmatics.

AIM: To assess whether variation in rs37972 is associated with altered ICS efficacy in north European asthmatic children and young adults with a reported use of ICS.

PATIENTS & METHODS: rs37972 was genotyped in three cohort studies of asthmatic children with a reported use of ICS. As an indicator for asthma exacerbations, asthma-related hospital visits and oral corticosteroid use were studied. Asthma control was assessed using a questionnaire.

RESULTS: rs37972 T allele was not significantly associated with an increased risk of oral corticosteroid use (summary odds ratio: 1.20; 95% CI: 0.99-1.45), an increased risk of asthma-related hospital visits (summary odds ratio: 1.07; 95% CI: 0.89-1.29), uncontrolled symptoms (summary odds ratio: 1.01; 95% CI: 0.75-1.36) or higher ICS dosages (summary β: 0.01, 95% CI: -0.06-0.08).

CONCLUSION: Variation in GLCCI1 rs37972 genotype does not seem to affect ICS efficacy in north European asthmatic children. Original submitted 26 November 2013; Revision submitted 13 February 2014.

Original language	English
Pages (from-to)	799-806
Number of pages	8
Journal	The Pharmacogenomics Journal
Volume	15
Issue number	6
DOIs	https://doi.org/10.2217/pgs.14.37
Publication status	Published - Apr 2014

Keywords

Administration, Inhalation
Adolescent
Adrenal Cortex Hormones
Adult
Anti-Asthmatic Agents
Asthma
Child
Child, Preschool
Cohort Studies
European Continental Ancestry Group
Humans
Pediatrics
Pharmacogenetics
Receptors, Glucocorticoid
Young Adult

Access to Document

10.2217/pgs.14.37

Cite this

Vijverberg, S. J. H., Tavendale, R., Leusink, M., Koenderman, L., Raaijmakers, J. A. M., Postma, D. S., Koppelman, G. H., Turner, S. W., Mukhopadhyay, S., Palmer, C. N. A., Maitland-van der Zee, A. H., & Turner, S. W. (2014). Pharmacogenetic analysis of GLCCI1 in three north European pediatric asthma populations with a reported use of inhaled corticosteroids. The Pharmacogenomics Journal, 15(6), 799-806. https://doi.org/10.2217/pgs.14.37

Vijverberg, SJH, Tavendale, R, Leusink, M, Koenderman, L, Raaijmakers, JAM, Postma, DS, Koppelman, GH, Turner, SW, Mukhopadhyay, S, Palmer, CNA, Maitland-van der Zee, AH & Turner, SW 2014, 'Pharmacogenetic analysis of GLCCI1 in three north European pediatric asthma populations with a reported use of inhaled corticosteroids', The Pharmacogenomics Journal, vol. 15, no. 6, pp. 799-806. https://doi.org/10.2217/pgs.14.37

@article{7be8b2cefc814e908bb3669c0df9f3e0,

title = "Pharmacogenetic analysis of GLCCI1 in three north European pediatric asthma populations with a reported use of inhaled corticosteroids",

abstract = "BACKGROUND: GLCCI1 rs37972 has previously been associated with decreased lung function improvement upon treatment with inhaled corticosteroids (ICS) in asthmatics.AIM: To assess whether variation in rs37972 is associated with altered ICS efficacy in north European asthmatic children and young adults with a reported use of ICS.PATIENTS & METHODS: rs37972 was genotyped in three cohort studies of asthmatic children with a reported use of ICS. As an indicator for asthma exacerbations, asthma-related hospital visits and oral corticosteroid use were studied. Asthma control was assessed using a questionnaire.RESULTS: rs37972 T allele was not significantly associated with an increased risk of oral corticosteroid use (summary odds ratio: 1.20; 95% CI: 0.99-1.45), an increased risk of asthma-related hospital visits (summary odds ratio: 1.07; 95% CI: 0.89-1.29), uncontrolled symptoms (summary odds ratio: 1.01; 95% CI: 0.75-1.36) or higher ICS dosages (summary β: 0.01, 95% CI: -0.06-0.08).CONCLUSION: Variation in GLCCI1 rs37972 genotype does not seem to affect ICS efficacy in north European asthmatic children. Original submitted 26 November 2013; Revision submitted 13 February 2014.",

keywords = "Administration, Inhalation, Adolescent, Adrenal Cortex Hormones, Adult, Anti-Asthmatic Agents, Asthma, Child, Child, Preschool, Cohort Studies, European Continental Ancestry Group, Humans, Pediatrics, Pharmacogenetics, Receptors, Glucocorticoid, Young Adult",

author = "Vijverberg, {Susanne J H} and Roger Tavendale and Maarten Leusink and Leo Koenderman and Raaijmakers, {Jan A M} and Postma, {Dirkje S} and Koppelman, {Gerard H} and Turner, {Steve W} and Somnath Mukhopadhyay and Palmer, {Colin N A} and {Maitland-van der Zee}, {Anke Hilse} and Turner, {Stephen William}",

year = "2014",

month = apr,

doi = "10.2217/pgs.14.37",

language = "English",

volume = "15",

pages = "799--806",

journal = "The Pharmacogenomics Journal",

issn = "1470-269X",

publisher = "Nature Publishing Group",

number = "6",

}

TY - JOUR

T1 - Pharmacogenetic analysis of GLCCI1 in three north European pediatric asthma populations with a reported use of inhaled corticosteroids

AU - Vijverberg, Susanne J H

AU - Tavendale, Roger

AU - Leusink, Maarten

AU - Koenderman, Leo

AU - Raaijmakers, Jan A M

AU - Postma, Dirkje S

AU - Koppelman, Gerard H

AU - Turner, Steve W

AU - Mukhopadhyay, Somnath

AU - Palmer, Colin N A

AU - Maitland-van der Zee, Anke Hilse

AU - Turner, Stephen William

PY - 2014/4

Y1 - 2014/4

N2 - BACKGROUND: GLCCI1 rs37972 has previously been associated with decreased lung function improvement upon treatment with inhaled corticosteroids (ICS) in asthmatics.AIM: To assess whether variation in rs37972 is associated with altered ICS efficacy in north European asthmatic children and young adults with a reported use of ICS.PATIENTS & METHODS: rs37972 was genotyped in three cohort studies of asthmatic children with a reported use of ICS. As an indicator for asthma exacerbations, asthma-related hospital visits and oral corticosteroid use were studied. Asthma control was assessed using a questionnaire.RESULTS: rs37972 T allele was not significantly associated with an increased risk of oral corticosteroid use (summary odds ratio: 1.20; 95% CI: 0.99-1.45), an increased risk of asthma-related hospital visits (summary odds ratio: 1.07; 95% CI: 0.89-1.29), uncontrolled symptoms (summary odds ratio: 1.01; 95% CI: 0.75-1.36) or higher ICS dosages (summary β: 0.01, 95% CI: -0.06-0.08).CONCLUSION: Variation in GLCCI1 rs37972 genotype does not seem to affect ICS efficacy in north European asthmatic children. Original submitted 26 November 2013; Revision submitted 13 February 2014.

AB - BACKGROUND: GLCCI1 rs37972 has previously been associated with decreased lung function improvement upon treatment with inhaled corticosteroids (ICS) in asthmatics.AIM: To assess whether variation in rs37972 is associated with altered ICS efficacy in north European asthmatic children and young adults with a reported use of ICS.PATIENTS & METHODS: rs37972 was genotyped in three cohort studies of asthmatic children with a reported use of ICS. As an indicator for asthma exacerbations, asthma-related hospital visits and oral corticosteroid use were studied. Asthma control was assessed using a questionnaire.RESULTS: rs37972 T allele was not significantly associated with an increased risk of oral corticosteroid use (summary odds ratio: 1.20; 95% CI: 0.99-1.45), an increased risk of asthma-related hospital visits (summary odds ratio: 1.07; 95% CI: 0.89-1.29), uncontrolled symptoms (summary odds ratio: 1.01; 95% CI: 0.75-1.36) or higher ICS dosages (summary β: 0.01, 95% CI: -0.06-0.08).CONCLUSION: Variation in GLCCI1 rs37972 genotype does not seem to affect ICS efficacy in north European asthmatic children. Original submitted 26 November 2013; Revision submitted 13 February 2014.

KW - Administration, Inhalation

KW - Adolescent

KW - Adrenal Cortex Hormones

KW - Adult

KW - Anti-Asthmatic Agents

KW - Asthma

KW - Child

KW - Child, Preschool

KW - Cohort Studies

KW - European Continental Ancestry Group

KW - Humans

KW - Pediatrics

KW - Pharmacogenetics

KW - Receptors, Glucocorticoid

KW - Young Adult

U2 - 10.2217/pgs.14.37

DO - 10.2217/pgs.14.37

M3 - Article

C2 - 24897287

SN - 1470-269X

VL - 15

SP - 799

EP - 806

JO - The Pharmacogenomics Journal

JF - The Pharmacogenomics Journal

IS - 6

ER -

Pharmacogenetic analysis of GLCCI1 in three north European pediatric asthma populations with a reported use of inhaled corticosteroids

Abstract

Keywords

Access to Document

Fingerprint

Cite this